Nevakar

Nevakar is a private, clinical-stage biotech company repositioning established drugs for improved outcomes in ophthalmology through novel formulations and delivery systems. Its strategy leverages known active ingredients to potentially accelerate development and reduce risk. The company's most advanced program, NVK002 for pediatric myopia progression, is under regulatory review in China and has completed Phase 3 trials in the US, positioning it as a near-term catalyst. Nevakar's business model spans both therapeutics and a proprietary drug delivery platform.

Focuses on repositioning known drugs through innovative ophthalmic formulations and advanced drug delivery technologies to improve efficacy, safety, and patient compliance.

In pediatric myopia, Nevakar's Vyluma competes with other developers of low-dose atropine formulations like Eyenovia, as well as the widespread use of off-label compounded pharmacies. In broader ophthalmic drug delivery, it faces large, established players like Alcon, Novartis, and Regeneron, as well as specialized biotechs.